Operose Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Operose Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-500	Closed	-$3.52K	–	760
2023 Q2	$3.52K	Buy	+500	New	+$3.58K	﹤0.01%	321

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Operose Advisors's IOVA Position: Q3 2023 in Review

Operose Advisors sold out of Iovance Biotherapeutics (IOVA) in Q3 2023, closing a stake of 500 shares — an estimated $3.52K sold.

Operose Advisors first reported a position in IOVA in Q2 2023 and held it in 1 quarter. The position peaked at $3.52K in Q2 2023. 227 funds tracked by Wall St. Rank hold IOVA as of Q3 2023.

Operose Advisors reported no remaining Iovance Biotherapeutics position as of Q3 2023 after selling out during the quarter.
Operose Advisors sold 500 Iovance Biotherapeutics shares in Q3 2023, an estimated $3.52K.
Operose Advisors first reported a position in Iovance Biotherapeutics in Q2 2023 and held it in 1 quarter.
Operose Advisors's Iovance Biotherapeutics position peaked at $3.52K in Q2 2023.
227 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2023.

Based on Operose Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.